4th ADC Linker and Conjugation Summit

Memo

ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution is placing unprecedented pressure on linker architecture and conjugation chemistry to control stability, reduce off-target toxicity, overcome tumor resistance, and maintain manufacturability. To meet these challenges head on, the 4th ADC Linker and Conjugation Summit offers a highly technical, deeply curated environment built specifically for specialists working at the cutting edge of ADC chemistry. At this summit, you aren't lost in a crowd, you're surrounded by peers who share the same job titles, scientific focus, and day-to-day challenges. Every session is built for specialists, every conversation is relevant, and every detail is designed to advance real chemistry solutions. Over three focused days, 80+ ADC chemists, protein engineers, and translational scientists will dissect the core chemistry questions shaping next generation ADC performance. With 20+ expert-led case studies from leading biopharma and biotech innovators, you'll gain actionable insights to engineer homogeneous ADCs, prevent premature payload release, enable orthogonal dual payload systems, mitigate hydrophobicity driven aggregation, and integrate predictive modeling into platform design. Through hands-on workshops, technical debates, and collaborative networking, this summit gives you the rare opportunity to shape the linker and conjugation strategies that will define the next decade of ADC development. URLs:Tickets: https://go.evvnt.com/3532328-2?pid=5569Brochure: https://go.evvnt.com/3532328-3?pid=5569 Date and Time: Tuesday, 28 July 2026 at 08:00 - Thursday, 30 July 2026 at 16:00 Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Conference + Workshop Day - Drug Developer Pricing: USD 4397.00,Conference Only - Drug Developer Pricing: USD 3099.00,Conference + Workshop Day - Academic Pricing: USD 3797.00,Conference Only - Academic Pricing: USD 2699.00,Conference + Workshop Day - Service Provider Pricing: USD 5297.00,Conference Only - Service Provider Pricing: USD 3799.00 Speakers: Sujiet Puthenveetil, Director of Antibody Drug Conjugates and Radioconjugates, AstraZeneca, Anokha Ratnayake, Director Discovery Chemistry, Former Nurix Therapeutics, David Liu, Senior Director Analytical Chemistry, Exelixis, Filippo Mulinacci, Chief Business Officer, Araris Biotech, Gaston Soria, Co-Founder and Chief Scientific Officer, OncoPrecision, Jagath Reddy Junutula, President, Chief Executive Officer and Co-Founder, Aarvik Therapeutics, Khuloud Takrouri, Executive Director and Head of Chemistry, Orum Therapeutics, Manel Merabet, Chief Development Officer, SKYMAB Biotherapeutics, Meddy El Alaoui, Co-Founder and Chief Executive Officer, AbTx, Michael Torres, Chief Executive Officer, CrossBridge Bio, Paul Sauter, Senior Director Chemistry and Bioconjugation, VERAXA, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Romas Kudirka, Vice President of ADCs, Ridge Bio, Sara Wichner, Scientist 4, Genentech, Tara Arvedson, Chief Scientific Officer, Hexagon Bio, Yasuaki Anami, Senior Scientist, CrossBridge Bio, Sampat Ingale, Senior Director of Peptide and Protein Chemistry, Biohaven, Marco Lobba, Chief Executive Officer, CatenaBio, Ravi Singh, Senior Scientist, Sutro Biopharma, Ning Wang, Postdoctoral Research Fellow, University College London, Peter Szijj, Postdoctoral Scientist Bertozzi Group, Stanford University